Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513526-27-00

Acronym

15-167

Enrollment

200

Registered

2024-05-29

Start date

2018-02-23

Completion date

Unknown

Last updated

2025-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

secondary or quaternary peritonitis, sepsis

Brief summary

Change in multiple organ failure (MOF) score (determined in the organs lung, heart, kidney, liver, blood) from baseline to day 7 after source control, in the course of peritonitis.

Detailed description

Death within 28 days, Death within 90 days, Change in MOF score from baseline to day 5, Multi-organ failure (> 4 MOF points) on day 7

Interventions

DRUGPentaglobin 50 g/l Infusionslösung

DRUGPentaglobin 50 mg/ml Infusionslösung

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in multiple organ failure (MOF) score (determined in the organs lung, heart, kidney, liver, blood) from baseline to day 7 after source control, in the course of peritonitis.	—

Secondary

Measure	Time frame
Death within 28 days, Death within 90 days, Change in MOF score from baseline to day 5, Multi-organ failure (> 4 MOF points) on day 7	—

Countries

Austria, Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026